FDA accepts Eisai’s sBLA for intravenous LEQEMBI to treat early Alzheimer’s

The FDA is reviewing a monthly IV dose of LEQEMBI for early Alzheimer’s treatment. Credit: Milad Fakurian on Unsplash.



  • Eisai